Featured Research

from universities, journals, and other organizations

"Super Aspirin" Holds Long-Term Benefits For Some Patients Who Undergo Balloon Angioplasty

Date:
August 18, 1997
Source:
Thomas Jefferson University
Summary:
An intravenous "super aspirin" called abciximab (ReoPro™, Centocor, Inc., Malvern, PA) administered in the catheterization laboratory before an angioplasty can prevent platelets from sticking to arterial walls and reclogging vessels after the procedure.

While innovative techniques and catheters, including coronary stents, have dramatically improved success rates for nonsurgical coronary revascularization, complications following balloon angioplasty remain an important problem associated with mortality.

Related Articles


An intravenous "super aspirin" called abciximab (ReoPro™, Centocor, Inc., Malvern, PA) administered in the catheterization laboratory before an angioplasty can prevent platelets from sticking to arterial walls and reclogging vessels after the procedure. Results of a multicenter study published in the August 13 issue of The Journal of the American Medical Association (JAMA) demonstrate a favorable effect on long-term outcome and survival in selected patients treated with ReoPro™.

In an editorial that accompanies the study, David L. Fischman, MD, associate professor of medicine, division of cardiology, Jefferson Medical College, Philadelphia, and associate director, cardiac catheterization laboratory at Thomas Jefferson University Hospital, recognizes the vast advantages of ReoPro™ but points out that patient profiles, drug costs and other interventional alternatives are issues to consider when deciding who should receive this "super aspirin."

In his editorial, Dr. Fischman notes that the multicenter study, which is a three-year follow-up to an initial study of ReoPro™, led by Eric J. Topol, MD, of the Cleveland Clinic Foundation, Ohio, shows that the benefits of ReoPro™ are greatest in the highest risk patients with acute heart attack or medically unstable angina. "The Topol study suggests a remarkable 60 percent reduction in mortality at three years in this select group treated with ReoPro™ compared with the group treated with placebo," said Dr. Fischman.

While pretreatment with ReoPro™ is highly effective, its average cost is estimated at $1,350 per patient dose. "The cost of this drug should bring significant attention to the question of who should receive it," said Dr. Fischman. "The issue of cost-effectiveness is vital to understanding whether or not ReoPro™ should be used in lower risk patient populations."

Dr. Fischman suggests that further investigation is necessary to address this issue. "Future development of oral agents similar to ReoPro™ promises to further expand the use of these agents to a broader spectrum of patients with ischemic heart disease," he said.

Michael P. Savage, M.D., associate professor of medicine, division of cardiology, Jefferson Medical College, and director of the cardiac catheterization laboratory at Thomas Jefferson University Hospital, contributed to the editorial.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. ""Super Aspirin" Holds Long-Term Benefits For Some Patients Who Undergo Balloon Angioplasty." ScienceDaily. ScienceDaily, 18 August 1997. <www.sciencedaily.com/releases/1997/08/970818052751.htm>.
Thomas Jefferson University. (1997, August 18). "Super Aspirin" Holds Long-Term Benefits For Some Patients Who Undergo Balloon Angioplasty. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/1997/08/970818052751.htm
Thomas Jefferson University. ""Super Aspirin" Holds Long-Term Benefits For Some Patients Who Undergo Balloon Angioplasty." ScienceDaily. www.sciencedaily.com/releases/1997/08/970818052751.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins